HK1250944A1 - 用於治疗癌症的方法 - Google Patents
用於治疗癌症的方法 Download PDFInfo
- Publication number
- HK1250944A1 HK1250944A1 HK18110438.9A HK18110438A HK1250944A1 HK 1250944 A1 HK1250944 A1 HK 1250944A1 HK 18110438 A HK18110438 A HK 18110438A HK 1250944 A1 HK1250944 A1 HK 1250944A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- treating cancer
- compound
- kits
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149349P | 2015-04-17 | 2015-04-17 | |
| US201562149349P | 2015-04-17 | ||
| US201662280947P | 2016-01-20 | 2016-01-20 | |
| US201662280947P | 2016-01-20 | ||
| PCT/US2016/028177 WO2016168856A1 (en) | 2015-04-17 | 2016-04-18 | Methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1250944A1 true HK1250944A1 (zh) | 2019-01-18 |
Family
ID=55854799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18110438.9A HK1250944A1 (zh) | 2015-04-17 | 2016-04-18 | 用於治疗癌症的方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180085341A1 (enExample) |
| EP (1) | EP3283069A1 (enExample) |
| JP (1) | JP2018511643A (enExample) |
| KR (1) | KR20180006918A (enExample) |
| CN (1) | CN107666906A (enExample) |
| AU (1) | AU2016247319A1 (enExample) |
| BR (1) | BR112017022281A2 (enExample) |
| CA (1) | CA2983010A1 (enExample) |
| EA (1) | EA201792287A1 (enExample) |
| HK (1) | HK1250944A1 (enExample) |
| IL (1) | IL255022A0 (enExample) |
| MX (1) | MX2017013360A (enExample) |
| PH (1) | PH12017501879A1 (enExample) |
| SG (2) | SG11201708504XA (enExample) |
| TW (1) | TW201713327A (enExample) |
| WO (1) | WO2016168856A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027443T2 (en) | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors |
| JP6433085B2 (ja) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
| JP2019506392A (ja) * | 2016-01-20 | 2019-03-07 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| EP3678663A4 (en) * | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| EP3865130A4 (en) | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER |
| EP3705893A1 (en) * | 2019-03-05 | 2020-09-09 | Humanitas Mirasole S.p.A. | Methods to assess the risk of being affected by prostate cancer |
| TW202102207A (zh) * | 2019-03-27 | 2021-01-16 | 新加坡商新加坡保健服務集團有限公司 | 對於癌病具有治療意義的生物標記 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027443T2 (en) | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors |
| CN103002890A (zh) | 2010-03-19 | 2013-03-27 | 波士顿生物医学公司 | 靶向癌症干细胞的新的化合物和组合物 |
| CN103025159A (zh) | 2010-03-19 | 2013-04-03 | 波士顿生物医学公司 | 靶向癌症干细胞的新方法 |
| EP2681203A4 (en) | 2011-03-04 | 2014-07-30 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd | NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES |
| US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| JP6433085B2 (ja) * | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
| JP2019506392A (ja) * | 2016-01-20 | 2019-03-07 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
-
2016
- 2016-04-18 SG SG11201708504XA patent/SG11201708504XA/en unknown
- 2016-04-18 TW TW105112097A patent/TW201713327A/zh unknown
- 2016-04-18 KR KR1020177033135A patent/KR20180006918A/ko not_active Withdrawn
- 2016-04-18 AU AU2016247319A patent/AU2016247319A1/en not_active Abandoned
- 2016-04-18 US US15/566,919 patent/US20180085341A1/en not_active Abandoned
- 2016-04-18 EA EA201792287A patent/EA201792287A1/ru unknown
- 2016-04-18 HK HK18110438.9A patent/HK1250944A1/zh unknown
- 2016-04-18 JP JP2017554403A patent/JP2018511643A/ja active Pending
- 2016-04-18 CN CN201680032355.6A patent/CN107666906A/zh active Pending
- 2016-04-18 BR BR112017022281A patent/BR112017022281A2/pt not_active Application Discontinuation
- 2016-04-18 SG SG10201900564WA patent/SG10201900564WA/en unknown
- 2016-04-18 MX MX2017013360A patent/MX2017013360A/es unknown
- 2016-04-18 CA CA2983010A patent/CA2983010A1/en not_active Abandoned
- 2016-04-18 WO PCT/US2016/028177 patent/WO2016168856A1/en not_active Ceased
- 2016-04-18 EP EP16723854.2A patent/EP3283069A1/en not_active Withdrawn
-
2017
- 2017-10-15 IL IL255022A patent/IL255022A0/en unknown
- 2017-10-18 PH PH12017501879A patent/PH12017501879A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016168856A1 (en) | 2016-10-20 |
| JP2018511643A (ja) | 2018-04-26 |
| IL255022A0 (en) | 2017-12-31 |
| CN107666906A (zh) | 2018-02-06 |
| EA201792287A1 (ru) | 2018-03-30 |
| BR112017022281A2 (pt) | 2018-07-10 |
| AU2016247319A1 (en) | 2017-11-02 |
| MX2017013360A (es) | 2018-08-01 |
| TW201713327A (zh) | 2017-04-16 |
| KR20180006918A (ko) | 2018-01-19 |
| SG10201900564WA (en) | 2019-02-27 |
| SG11201708504XA (en) | 2017-11-29 |
| EP3283069A1 (en) | 2018-02-21 |
| CA2983010A1 (en) | 2016-10-20 |
| PH12017501879A1 (en) | 2018-03-05 |
| US20180085341A1 (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
| HK1258098A1 (zh) | 治疗癌症的方法 | |
| HK1250944A1 (zh) | 用於治疗癌症的方法 | |
| EP3258966A4 (en) | Methods, compositions, and kits for treatment of cancer | |
| EP3548071A4 (en) | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| EP3393475A4 (en) | METHODS OF TREATING CANCER | |
| WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
| IL261015A (en) | History of methylamine as lysis oxidase inhibitors for cancer treatment | |
| IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
| EP4616910A3 (en) | Pcna inhibitors | |
| MX2016009663A (es) | Derivados de icariina. | |
| EP3394047A4 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| EP4169918B8 (en) | Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer | |
| PH12017501880A1 (en) | Methods for treating cancer | |
| EP3487999A4 (en) | METHODS OF TREATING CANCER | |
| EP3296294A4 (en) | Compound for treating or preventing breast cancer | |
| EP3303289A4 (en) | Compounds and methods for treating cancer | |
| EP3592357A4 (en) | METHOD OF TREATMENT OF CANCER | |
| EP3268028A4 (en) | Compositions and methods for treating cancer | |
| EP3242681B8 (en) | Novel compounds for the treatment of cancer | |
| EP3285763A4 (en) | Compositions for the treatment of cancer | |
| HK40093247A (zh) | 治疗癌症的组合物及方法 | |
| HK40091841A (zh) | 用於治疗癌症的方法和组合物 |